Kindred Biosciences found using ticker (KIN) now have 7 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 16 and 9 calculating the mean target price we have 11.18. With the stocks previous close at 4.86 this indicates there is a potential upside of 130.0%. The 50 day MA is 4.85 while the 200 day moving average is 4.51. The company has a market cap of $211m. Find out more information at: http://www.kindredbio.com
Kindred Biosciences, a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.